XML 53 R15.htm IDEA: XBRL DOCUMENT
v3.19.3

Share-Based Compensation Plans | 6 Months Ended
--- | ---
Aug. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Share-Based Compensation Plans | Share-Based Compensation Plans We have equity awards outstanding under several share-based compensation plans. During the three and six months ended August 31, 2019, we had the following share-based compensation activity:
• | We issued 1,048 and 2,304 shares to non-employee Board members with a total grant date fair value of $0.1 and $0.2 million, respectively, and share prices of $134.21 and $121.99, respectively.
• | We granted time-vested restricted stock units ("RSUs") that may be settled for 8 and 3,279 shares of common stock, respectively. The RSU grants have a weighted average grant price of $150.86 and $111.51 per share, respectively. For the three months ended August 31, 2019, the total award fair value was insignificant. For the six months ended August 31, 2019, the total award fair value at date of grant was $0.4 million.
• | We granted time-vested restricted stock awards ("RSAs") that may be vested for 4,920 and 45,772 shares of common stock, respectively. The RSA grants have a weighted average grant price of $138.86 and $113.98 per share, respectively, for a total award fair value at date of grant of $0.7 million and $5.2 million, respectively.
• | There were no grants of performance-based stock units ("PSUs") during the three months ended August 31, 2019. For the six months ended August 31, 2019, we granted PSUs that may be settled for 6,088 shares of common stock. The PSU grants have a weighted average grant price of $110.85 per share for a total award fair value at date of grant of $0.7 million.
• | There were no grants of performance-based restricted stock awards ("PSAs") during the three months ended August 31, 2019. For the six months ended August 31, 2019, we granted PSAs that are targeted to be vested for 122,402 shares of common stock. The PSA grants have a weighted average grant price of $110.85 per share for a total award fair value at date of grant of $13.6 million.
• | RSUs for 3,489 and 66,329 shares vested and settled, respectively, with a total fair value at settlement of $0.5 and $7.6 million and a weighted average share price of $146.26 and $114.58, respectively.
• | There were no PSUs shares vested and settled during the three months ended August 31, 2019. For the six months ended August 31, 2019, there were 108,572 shares vested and settled with a total fair value at settlement of $14.7 million, and a weighted average share price of $135.85.
• | RSAs for 928 shares vested and settled with a total fair value at settlement of $0.1 million and a weighted average share price of $150.86 during the three and six month periods ended August 31, 2019.
• | Employees exercised stock options to purchase 26,368 and 61,765 shares of common stock, respectively.
• | There were no purchases of common stock under the employee stock purchase plan during the three months ended August 31, 2019. For the six months ended August 31, 2019, employees purchased 14,790 shares of common stock under the employee stock purchase plan at an average price of $95.29 per share.
We recorded the following share-based compensation expense in SG&A for the periods shown below:
| Three Months Ended August 31,
(in thousands, except per share data) | 2019 |  | 2018
Stock options | $ | 35 |  |  | $ | 219 |
Directors stock compensation | 141 |  |  | 123 |
Performance based and other stock awards | 6,205 |  |  | 4,347 |
Employee stock purchase plan | — |  |  | — |
Share-based compensation expense | 6,381 |  |  | 4,689 |
Less income tax benefits | (514 | ) |  | (341 | )
Share-based compensation expense, net of income tax benefits | $ | 5,867 |  |  | $ | 4,348 |
Impact of share-based compensation on earnings per share from continuing operations: |  |  |
Basic | $ | 0.23 |  |  | $ | 0.16 |
Diluted | $ | 0.23 |  |  | $ | 0.16 |
| Six Months Ended August 31,
(in thousands, except per share data) | 2019 |  | 2018
Stock options | $ | 151 |  |  | $ | 527 |
Directors stock compensation | 281 |  |  | 246 |
Performance based and other stock awards | 13,228 |  |  | 9,918 |
Employee stock purchase plan | 325 |  |  | 322 |
Share-based compensation expense | 13,985 |  |  | 11,013 |
Less income tax benefits | (1,091 | ) |  | (611 | )
Share-based compensation expense, net of income tax benefits | $ | 12,894 |  |  | $ | 10,402 |
Impact of share-based compensation on earnings per share from continuing operations: |  |  |
Basic | $ | 0.51 |  |  | $ | 0.39 |
Diluted | $ | 0.51 |  |  | $ | 0.39 |

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration